David N. Gill

David N. Gill, listed as board member, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Evolus, Inc., Strongbridge Biopharma plc and Y-mAbs Therapeutics, Inc. In total, 15 filings cover trades dated from 14 May 2021 to 17 February 2026.

No open-market purchase appears, only 2 sales worth €110k. Other entries cover 11 share grants.

The latest filing, published on 19 February 2026, reports a share grant in Evolus, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.